This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene Higher on Revlimid Patent Case Document Release

Celgene (CELG - Get Report) shares are notably higher Wednesday on what appears to be an investor relief rally over the patent life of Revlimid, the company's biggest selling cancer drug. 

Documents pertaining to an upcoming pre-trial "Markman" hearing were made public which appear to favor Celgene over Natco, the generic drugmaker challenging certain Revlimid patents. That's the take of RBC analyst Michael Yee:

Markman briefing documents were released and our layman's interpretation is that CELG is generally well positioned. In the opposition filings, and beyond even the core fundamental arguments for the novelty and merits of the polymorph patent and other methods patents such as REMS system etc (CELG cites validity and infringement of 18 total patents and additional four new ones) CELG additionally also claims or notes NatCo has "unclean hands" (a notable defense mechanism) in part of their belief that NatCo's had illicit methods of obtaining Revlimid for testing and/or in their nature and part of limiting and stonewalling CELG's ability to get key testimony from a witness involved in getting NatCo the Revlimid for bioequivalance testing. As page 11 states "clearly Defendants have much to fear...and are willing to go to great lengths to prevent Celgene from obtaining his discovery."
Celgene shares are up 4.5% to $144.45 in mid-day trading. 

I wrote a backgrounder on Celgene and the Revlimid patent issues in last week's Biotech Stock Mailbag. Subesequently, the date of the Markman hearing was pushed back to May 15 from April 29.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs